A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Neoplasms, Metastases, Neoplasm
About this trial
This is an interventional treatment trial for Neoplasms focused on measuring Cancer, solid tumor, Advanced malignancy, Taxane therapy, Biopsy-proven diagnosis of advanced malignancy, Various solid tumors which are refractory
Eligibility Criteria
At least 18 years of age Life expectancy of at least 2 months Off all therapy for at least 3 weeks prior to study drug administration Biopsy-proven diagnosis of advanced malignancy Patients with solid tumors who have failed standard therapy Karnofsky Performance Status of 70% or 0-2 SWOG Performance Status Hemoglobin at least 9 White Blood Cell count of at least 3000/mm3 with absolute neutrophil count of at least 1500/mm3 Platelet count of at least 100,000/mm3 Serum Creatinine less than 2 mg/dL Transaminases less than 3X the upper limit of normal Patient must provide informed consent Serum Bilirubin less than 1.5 mg/dL
Sites / Locations
- Abraxis Bioscience, Inc.